{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:28:01Z","timestamp":1786116481884,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00059-026-05385-7","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:10:10Z","timestamp":1784880610000},"page":"318-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management von erh\u00f6htem Blutdruck und Bluthochdruck","Management of elevated blood pressure and hypertension"],"prefix":"10.1007","volume":"51","author":[{"given":"Raphael S.","family":"Schmieder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"14","key":"5385_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"Global Cardiovascular Risk, C","year":"2023","unstructured":"Global Cardiovascular Risk, C et\u00a0al (2023) Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med 389(14):1273\u20131285","journal-title":"N Engl J Med"},{"issue":"10517","key":"5385_CR2","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/S0140-6736(25)02208-1","volume":"406","author":"J Farrar","year":"2025","unstructured":"Farrar\u00a0J, Frieden\u00a0T (2025) WHO global report on hypertension 2025. The Lancet 406(10517):2318\u20132319","journal-title":"The Lancet"},{"issue":"10285","key":"5385_CR3","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"Blood Pressure Lowering Treatment Trialists, C","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists, C (2021) Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 397(10285):1625\u20131636","journal-title":"Lancet"},{"issue":"10022","key":"5385_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad\u00a0D et\u00a0al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a\u00a0systematic review and meta-analysis. Lancet 387(10022):957\u2013967","journal-title":"Lancet"},{"issue":"10258","key":"5385_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBDRF Collaborators","year":"2020","unstructured":"Collaborators\u00a0GBDRF (2020) Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1223\u20131249","journal-title":"Lancet"},{"issue":"25","key":"5385_CR6","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah\u00a0GA et\u00a0al (2023) Global Burden of Cardiovascular Diseases and Risks, 1990\u20132022. J\u00a0Am Coll Cardiol 82(25):2350\u20132473","journal-title":"J Am Coll Cardiol"},{"issue":"10507","key":"5385_CR7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0140-6736(25)01391-1","volume":"406","author":"X Guo","year":"2025","unstructured":"Guo\u00a0X et\u00a0al (2025) Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials. Lancet 406(10507):1009\u20131019","journal-title":"Lancet"},{"issue":"38","key":"5385_CR8","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy\u00a0JW et\u00a0al (2024) 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 45(38):3912\u20134018","journal-title":"Eur Heart J"},{"issue":"12","key":"5385_CR9","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia\u00a0G et\u00a0al (2023) 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J\u00a0Hypertens 41(12):1874\u20132071","journal-title":"J Hypertens"},{"key":"5385_CR10","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2023) Nationale VersorgungsLeitlinie Hypertonie \u2013 Langfassung, Version\u00a01.0."},{"issue":"10305","key":"5385_CR11","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"Blood Pressure Lowering Treatment Trialists, C","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists, C (2021) Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 398(10305):1053\u20131064","journal-title":"Lancet"},{"issue":"6","key":"5385_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003599","volume":"18","author":"AC Pinho-Gomes","year":"2021","unstructured":"Pinho-Gomes\u00a0AC et\u00a0al (2021) Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. PLoS Med 18(6):e1003599","journal-title":"PLoS Med"},{"issue":"11","key":"5385_CR13","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1161\/HYPERTENSIONAHA.123.21496","volume":"80","author":"Z Bidel","year":"2023","unstructured":"Bidel\u00a0Z et\u00a0al (2023) Sex-Specific Effects of Blood Pressure Lowering Pharmacotherapy for the Prevention of Cardiovascular Disease: An Individual Participant-Level Data Meta-Analysis. Hypertension 80(11):2293\u20132302","journal-title":"Hypertension"},{"issue":"9","key":"5385_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","volume":"10","author":"M Nazarzadeh","year":"2022","unstructured":"Nazarzadeh\u00a0M et\u00a0al (2022) Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol 10(9):645\u2013654","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"5385_CR15","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"DW Jones","year":"2025","unstructured":"Jones\u00a0DW et\u00a0al (2025) 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J\u00a0Am Coll Cardiol 86(18):1567\u20131678","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"5385_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","volume":"42","author":"JE Neter","year":"2003","unstructured":"Neter\u00a0JE et\u00a0al (2003) Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42(5):878\u2013884","journal-title":"Hypertension"},{"issue":"11","key":"5385_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding\u00a0JPH et\u00a0al (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"issue":"4","key":"5385_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1161\/HYPERTENSIONAHA.115.06853","volume":"67","author":"HC Gay","year":"2016","unstructured":"Gay\u00a0HC et\u00a0al (2016) Effects of Different Dietary Interventions on Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension 67(4):733\u2013739","journal-title":"Hypertension"},{"issue":"1","key":"5385_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/eurjpc\/zwaa141","volume":"29","author":"H Hanssen","year":"2022","unstructured":"Hanssen\u00a0H et\u00a0al (2022) Personalized exercise prescription in the prevention and treatment of arterial hypertension: a\u00a0Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension. Eur J Prev Cardiol 29(1):205\u2013215","journal-title":"Eur J Prev Cardiol"},{"issue":"20","key":"5385_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/bjsports-2022-106503","volume":"57","author":"JJ Edwards","year":"2023","unstructured":"Edwards\u00a0JJ et\u00a0al (2023) Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis of randomised controlled trials. Br J Sports Med 57(20):1317\u20131326","journal-title":"Br J Sports Med"},{"issue":"10347","key":"5385_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(22)00847-9","volume":"400","author":"GBDA Collaborators","year":"2022","unstructured":"Collaborators\u00a0GBDA (2022) Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet 400(10347):185\u2013235","journal-title":"Lancet"},{"issue":"14","key":"5385_CR22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang\u00a0W et\u00a0al (2021) Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med 385(14):1268\u20131279","journal-title":"N Engl J Med"},{"issue":"20","key":"5385_CR23","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"SR Group","year":"2021","unstructured":"Group\u00a0SR et\u00a0al (2021) Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 384(20):1921\u20131930","journal-title":"N Engl J Med"},{"issue":"5","key":"5385_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jamacardio.2019.6192","volume":"5","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan\u00a0M et\u00a0al (2020) Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol 5(5):576\u2013581","journal-title":"JAMA Cardiol"},{"issue":"3","key":"5385_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.113.02089","volume":"63","author":"G Reboldi","year":"2014","unstructured":"Reboldi\u00a0G et\u00a0al (2014) Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension 63(3):475\u2013482","journal-title":"Hypertension"},{"issue":"4","key":"5385_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jama.2019.21402","volume":"323","author":"JW McEvoy","year":"2020","unstructured":"McEvoy\u00a0JW et\u00a0al (2020) Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC\/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA 323(4):329\u2013338","journal-title":"JAMA"},{"issue":"21","key":"5385_CR27","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/eurheartj\/ehab111","volume":"42","author":"AP Jacobsen","year":"2021","unstructured":"Jacobsen\u00a0AP et\u00a0al (2021) A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment. Eur Heart J 42(21):2119\u20132129","journal-title":"Eur Heart J"},{"issue":"5","key":"5385_CR28","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1161\/HYPERTENSIONAHA.121.17766","volume":"78","author":"JW McEvoy","year":"2021","unstructured":"McEvoy\u00a0JW et\u00a0al (2021) Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-Hour Ambulatory Blood Pressure Measurements. Hypertension 78(5):1222\u20131231","journal-title":"Hypertension"},{"issue":"10","key":"5385_CR29","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1038\/s41440-025-02331-8","volume":"48","author":"Y Ohya","year":"2025","unstructured":"Ohya\u00a0Y et\u00a0al (2025) Key highlights of the Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025). Hypertens Res 48(10):2500\u20132511","journal-title":"Hypertens Res"},{"issue":"10305","key":"5385_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow\u00a0CK et\u00a0al (2021) Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet 398(10305):1043\u20131052","journal-title":"Lancet"},{"issue":"10305","key":"5385_CR31","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S0140-6736(21)01964-4","volume":"398","author":"T Kahan","year":"2021","unstructured":"Kahan\u00a0T (2021) Low-dose combination of blood pressure-lowering medicines. Lancet 398(10305):1022\u20131023","journal-title":"Lancet"},{"issue":"1","key":"5385_CR32","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYP.0000000000000203","volume":"79","author":"NK Choudhry","year":"2022","unstructured":"Choudhry\u00a0NK et\u00a0al (2022) Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension 79(1):e1\u2013e14","journal-title":"Hypertension"},{"issue":"6","key":"5385_CR33","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1097\/HJH.0000000000002398","volume":"38","author":"AJ Lawson","year":"2020","unstructured":"Lawson\u00a0AJ et\u00a0al (2020) Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J\u00a0Hypertens 38(6):1165\u20131173","journal-title":"J Hypertens"},{"issue":"2","key":"5385_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati\u00a0G et\u00a0al (2021) Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension 77(2):692\u2013705","journal-title":"Hypertension"},{"issue":"1","key":"5385_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41440-025-02497-1","volume":"49","author":"K Kario","year":"2026","unstructured":"Kario\u00a0K (2026) Implementation hypertension: a\u00a0new paradigm for global hypertension control in the JSH 2025, WHO 2025, and AHA\/ACC 2025 guideline era. Hypertension Research 49(1):1\u20136","journal-title":"Hypertension Research"},{"issue":"7404","key":"5385_CR36","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law\u00a0MR et\u00a0al (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404):1427\u20131427","journal-title":"BMJ"},{"issue":"30","key":"5385_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004071","volume":"95","author":"MA Paz","year":"2016","unstructured":"Paz\u00a0MA et\u00a0al (2016) Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore) 95(30):e4071","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"5385_CR38","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey\u00a0RM et\u00a0al (2018) Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension 72(5):e53\u2013e90","journal-title":"Hypertension"},{"issue":"10008","key":"5385_CR39","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams\u00a0B et\u00a0al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386(10008):2059\u20132068","journal-title":"Lancet"},{"issue":"16","key":"5385_CR40","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1001\/jama.2026.1221","volume":"335","author":"M Azizi","year":"2026","unstructured":"Azizi\u00a0M et\u00a0al (2026) Diagnosis and Management of Resistant Hypertension: A Review. Jama 335(16):1428\u20131439","journal-title":"Jama"},{"issue":"2","key":"5385_CR41","volume":"2","author":"TS Tam","year":"2017","unstructured":"Tam\u00a0TS et\u00a0al (2017) Eplerenone for hypertension. Cochrane Database Syst Rev 2(2):CD008996","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"5385_CR42","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/HYPERTENSIONAHA.111.00633","volume":"61","author":"GF DiBona","year":"2013","unstructured":"DiBona\u00a0GF (2013) Sympathetic nervous system and hypertension. Hypertension 61(3):556\u2013560","journal-title":"Hypertension"},{"issue":"15","key":"5385_CR43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","volume":"44","author":"E Barbato","year":"2023","unstructured":"Barbato\u00a0E et\u00a0al (2023) Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 44(15):1313\u20131330","journal-title":"Eur Heart J"},{"issue":"10","key":"5385_CR44","volume":"10","author":"E Abalos","year":"2018","unstructured":"Abalos\u00a0E et\u00a0al (2018) Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 10(10):CD002252","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"5385_CR45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1404595","volume":"372","author":"LA Magee","year":"2015","unstructured":"Magee\u00a0LA et\u00a0al (2015) Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 372(5):407\u2013417","journal-title":"N Engl J Med"},{"issue":"9","key":"5385_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102054","volume":"4","author":"SA Leonard","year":"2025","unstructured":"Leonard\u00a0SA et\u00a0al (2025) Comparative Effectiveness and Safety of Labetalol Versus Nifedipine for Treatment of Chronic Hypertension During Pregnancy. JACC Adv 4(9):102054","journal-title":"JACC Adv"},{"issue":"6","key":"5385_CR47","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/ehjcvp\/pvz082","volume":"6","author":"R Cifkova","year":"2020","unstructured":"Cifkova\u00a0R et\u00a0al (2020) Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother 6(6):384\u2013393","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"Suppl 1(Suppl 1","key":"5385_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ijgo.13763","volume":"154","author":"LC Poon","year":"2021","unstructured":"Poon\u00a0LC et\u00a0al (2021) A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics). Int J Gynaecol Obstet 154(Suppl 1(Suppl 1)):3\u201331","journal-title":"Int J Gynaecol Obstet"},{"key":"5385_CR49","unstructured":"Guideline of the German Society of Gynecology and Obstetrics (S2k -Level, A.R.N., . Hypertensive Disorders in Pregnancy: Diagnosis and Therapy"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-026-05385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-026-05385-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-026-05385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:02:05Z","timestamp":1786010525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-026-05385-7"}},"subtitle":["Risikoreduktion im Fokus","Focus on risk reduction"],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5385"],"URL":"https:\/\/doi.org\/10.1007\/s00059-026-05385-7","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.S.\u00a0Schmieder\n                      declares research support from non-profit organizations (Bayerisches Gesundheitsministerium, Deutsche Herzallianz, Dr. Rolf M.\u00a0Schwiete Stiftung) for the sponsorship of the VRONI study, and lecture fees from AstraZeneca.\n                      H.\u00a0Schunkert\n                      \u2019s declaration is attached (see list provided).","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}